country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-19162

Copy Link Print Information

Thiazolobenzimidazole

(Synonyms: NSC-625487)

Thiazolobenzimidazole (NSC-625487) is a highly potent nonnucleoside HIV-1 reverse transcriptase inhibitor. Thiazolobenzimidazole inhibits HIV-induced cell killing and viral replication in a variety of human cell lines.

For research use only. We do not sell to patients.

CAS No.: 138226-12-7
Formula: C₁₅H₁₀F₂N₂S
Molecular Weight:288.32

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

Thiazolobenzimidazole Chemical Structure

CAS No.: 138226-12-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

HIV-1

All HIV Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	50 μM Compound: TBZ	Cytotoxicity against CEM cells Cytotoxicity against CEM cells	[PMID: 17178227]
CCRF-CEM	CC₅₀	50 μM Compound: TBZ-1	Cytotoxicity against mock-infected CEM cells assessed as reduction of cell viability Cytotoxicity against mock-infected CEM cells assessed as reduction of cell viability	[PMID: 17349793]
CCRF-CEM	CC₅₀	50 μM Compound: TBZ-1	Cytotoxicity against human CEM cells by MTT assay Cytotoxicity against human CEM cells by MTT assay	[PMID: 18242784]
CCRF-CEM	EC₅₀	1.1 μM Compound: TBZ	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced syncytium formation after 4 days Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced syncytium formation after 4 days	[PMID: 17178227]
CCRF-CEM	EC₅₀	1.1 μM Compound: TBZ-1	Antiviral activity against HIV1 3B-induced cytopathic effect in CEM cells assessed as inhibition of virus-induced syncytium formation Antiviral activity against HIV1 3B-induced cytopathic effect in CEM cells assessed as inhibition of virus-induced syncytium formation	[PMID: 17349793]
CCRF-CEM	EC₅₀	1.1 μM Compound: TBZ-1	Antiviral activity against HIV1 3B replication in human CEM cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay Antiviral activity against HIV1 3B replication in human CEM cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay	[PMID: 18242784]
CCRF-CEM	EC₅₀	1.73 μM Compound: TBZ	Concentration required to protect CEM cells against Mutant E138K Strain Concentration required to protect CEM cells against Mutant E138K Strain	[PMID: 15857150]
CCRF-CEM	EC₅₀	13.8 μM Compound: TBZ	Concentration required to protect CEM cells against Mutant Y181C Strain Concentration required to protect CEM cells against Mutant Y181C Strain	[PMID: 15857150]
CCRF-CEM	EC₅₀	15.6 μM Compound: TBZ	Concentration required to protect CEM cells against Mutant K103N Strain Concentration required to protect CEM cells against Mutant K103N Strain	[PMID: 15857150]
CCRF-CEM	EC₅₀	3.12 μM Compound: TBZ	Concentration required to protect CEM cells against Mutant L100I Strain Concentration required to protect CEM cells against Mutant L100I Strain	[PMID: 15857150]
CCRF-CEM	EC₅₀	4.16 μM Compound: TBZ	Concentration required to protect CEM cells against Mutant Y188H Strain Concentration required to protect CEM cells against Mutant Y188H Strain	[PMID: 15857150]
CEM-SS	EC₅₀	0.52 mM Compound: TZB	In vitro 50% cellular protection of CEM-SS cells from HIV-1 induced cytopathicity. In vitro 50% cellular protection of CEM-SS cells from HIV-1 induced cytopathicity.	[PMID: 9435891]
MT4	CC₅₀	19.2 μM Compound: TBZ	Cytotoxicity against MT4 cells Cytotoxicity against MT4 cells	[PMID: 17178227]
MT4	CC₅₀	19.2 μM Compound: TBZ1	Cytotoxicity to reduce MT-4 cell viability by 50% Cytotoxicity to reduce MT-4 cell viability by 50%	[PMID: 11425562]
MT4	CC₅₀	19.2 μM Compound: TBZ-1	Cytotoxicity against mock-infected MT4 cells assessed as reduction of cell viability Cytotoxicity against mock-infected MT4 cells assessed as reduction of cell viability	[PMID: 17349793]
MT4	CC₅₀	19.2 μM Compound: TBZ-1	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18242784]
MT4	CC₅₀	50 μM Compound: TBZ	Cytotoxic concentration required to reduce MT-4 cell viability Cytotoxic concentration required to reduce MT-4 cell viability	[PMID: 15857150]
MT4	EC₅₀	0.35 μM Compound: TBZ	Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days	[PMID: 17178227]
MT4	EC₅₀	0.35 μM Compound: TBZ-1	Antiviral activity against HIV1 3B-induced cytopathic effect in MT4 cells assessed as inhibition of virus-induced syncytium formation Antiviral activity against HIV1 3B-induced cytopathic effect in MT4 cells assessed as inhibition of virus-induced syncytium formation	[PMID: 17349793]
MT4	EC₅₀	0.35 μM Compound: TBZ-1	Antiviral activity against HIV1 3B replication in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay Antiviral activity against HIV1 3B replication in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay	[PMID: 18242784]
MT4	EC₅₀	0.352 μM Compound: TBZ1	Anti-HIV activity to reduce HIV-1-induced cytopathic effect by 50% in MT-4 cells against HIV-1 IIIB Anti-HIV activity to reduce HIV-1-induced cytopathic effect by 50% in MT-4 cells against HIV-1 IIIB	[PMID: 11425562]
MT4	EC₅₀	1.1 μM Compound: TBZ	Concentration required to reduce HIV-1-induced cytopathic effect in MT-4 cells Concentration required to reduce HIV-1-induced cytopathic effect in MT-4 cells	[PMID: 15857150]
MT4	EC₅₀	1.39 μM Compound: TBZ	Compound was tested for inhibition of the cytopathic effects of HIV-1 (IIIB) in MT-4 cells Compound was tested for inhibition of the cytopathic effects of HIV-1 (IIIB) in MT-4 cells	[PMID: 15857150]
MT4	EC₅₀	1100 nM Compound: 81; NSC625487	Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against HIV-1 induced cytopathicity by MTT assay Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against HIV-1 induced cytopathicity by MTT assay	[PMID: 26509831]
MT4	IC₅₀	14.6 μM Compound: TBZ1	Evaluated for the inhibition of replication of HIV-1 IIIB or HIV-2 (ROD) in MT-4 cells by using [3H]-dGTP as the radiolabeled substrate Evaluated for the inhibition of replication of HIV-1 IIIB or HIV-2 (ROD) in MT-4 cells by using [3H]-dGTP as the radiolabeled substrate	[PMID: 11425562]

Chemical Information

CAS No. 138226-12-7
Molecular Weight 288.32
Formula C₁₅H₁₀F₂N₂S
SMILES

FC1=C(C2SCC3=NC4=CC=CC=C4N32)C(F)=CC=C1
Synonyms

NSC-625487
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Buckheit RW Jr, et al. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 1993 Jul;21(3):247-65. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Thiazolobenzimidazole

All HIV Isoforms

Biological Activity

Chemical Information

Purity & Documentation

References

Calculators

Help & FAQs

Thiazolobenzimidazole Related Classifications

HY-19162 Related Classifications